论文部分内容阅读
目的:探讨雷贝拉唑联合多潘立酮治疗胃食管反流病的临床疗效及安全性。方法:选取我院收治的64例胃食管反流病患者作为研究,将其随机均分为观察组和对照组,对照组采用雷贝拉唑治疗,观察组采用雷贝拉唑联合多潘立酮治疗,比较两组临床疗效及复发率。结果:观察组治疗有效率为90.7%,高于对照组的75.0%,差异比较显著(P<0.05);治疗后随访3个月,观察组复发率为9.4%,低于对照组的37.5%,差异比较有统计学意义(P<0.05)。两组治疗期间未出现严重不良反应。结论:采用雷贝拉唑联合多潘立酮治疗胃食管反流病临床疗效确切,安全性高,值得临床进一步推广应用。
Objective: To investigate the clinical efficacy and safety of rabeprazole combined with domperidone in the treatment of gastroesophageal reflux disease. Methods: Sixty-four patients with gastroesophageal reflux disease admitted to our hospital were randomly divided into observation group and control group. The control group was treated with rabeprazole. The observation group was treated with rabeprazole and domperidone, The clinical efficacy and recurrence rate were compared between the two groups. Results: The effective rate of observation group was 90.7%, higher than that of the control group (75.0%) (P <0.05). After 3 months of follow-up, the recurrence rate of the observation group was 9.4%, which was lower than that of the control group (37.5% , The difference was statistically significant (P <0.05). No serious adverse reactions occurred during the two groups. Conclusion: Rabeprazole combined with domperidone in the treatment of gastroesophageal reflux disease has definite clinical curative effect and high safety. It is worth further clinical application.